Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.
相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2020
已完成
1
25.0%
招募中
1
25.0%
终止
2
50.0%
暂无批准数据
- Ovid Therapeutics successfully completed a Phase 1 study of OV350, the first-ever direct activator of KCC2 (potassium-chloride cotransporter 2) tested in humans, demonstrating good safety profile with no treatment-related serious adverse events. - The study achieved pharmacologically active concentrations and showed exploratory qEEG findings consistent with expected KCC2 modulation effects in the brain, supporting the therapeutic potential of this novel mechanism. - Results support advancement of Ovid's oral KCC2 direct activator portfolio, with OV4071 planned for Phase 1/1b trials in Q2 2026 targeting psychosis in Parkinson's disease and Lewy body dementia. - The company also appointed Dr. Petra Kaufmann as Chief Medical Officer, bringing extensive CNS drug development experience from Novartis Gene Therapies and leadership in Zolgensma's global approval.
- Total M&A deal value in Alzheimer's disease jumped from $2 billion in 2022 to $18 billion in 2024, representing a 780% increase following the approval of disease-modifying treatments. - Biogen's Leqembi demonstrates superior safety with 12.6% ARIA-E incidence compared to Lilly's Kisunla at 24%, positioning it for greater market share despite both drugs' modest initial sales performance. - Major pharmaceutical companies including AbbVie, Sanofi, and Johnson & Johnson have made significant acquisitions totaling billions, signaling renewed confidence in Alzheimer's therapeutic development. - The FDA-approved Lumipulse blood test provides cost-effective diagnostic support for Leqembi at $200-$300 versus traditional PET scans costing $3,000-$5,000, improving patient access and clinical workflow integration.
- Sanofi has entered into a definitive merger agreement to acquire Vigil Neuroscience for $8.00 per share in cash upfront, with an additional $2.00 per share contingent value right tied to VG-3927's first commercial sale. - The acquisition strengthens Sanofi's neurology pipeline with VG-3927, a Phase 2-ready oral small molecule TREM2 agonist being developed for Alzheimer's disease, targeting microglial dysfunction in neurodegenerative disorders. - The transaction, valued at approximately $600 million including the potential CVR payment, is expected to close in the third quarter of 2025, with Vigil's monoclonal antibody program iluzanebart not included in the acquisition.
- Vigil Neuroscience is on track to report final analysis from the IGNITE Phase 2 trial of iluzanebart for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in Q2 2025, with plans to pursue accelerated approval. - The company's small molecule TREM2 agonist VG-3927 demonstrated positive Phase 1 results for Alzheimer's disease, showing favorable safety, CNS penetration, and robust target engagement, with Phase 2 trials planned for Q3 2025. - Preclinical data presented at the AD/PD™ 2025 conference highlighted VG-3927's unique synergistic activation with endogenous TREM2 ligands like amyloid-beta, potentially enhancing potency in regions of pathology.
- Pharmaceutical M&A activity is experiencing a significant rebound with major deals including Novartis's $1.7 billion acquisition of Regulus Therapeutics and Merck KGaA's $3.9 billion purchase of SpringWorks Therapeutics. - Small-cap biotechs are becoming prime acquisition targets as 22% of the sector now trades below cash value, the highest level in nine years, creating opportunities for pharma companies with strong balance sheets. - Major pharmaceutical companies including Pfizer, Bristol Myers Squibb, and Sanofi have signaled business development as a top priority, with Pfizer specifically targeting $10-15 billion acquisitions to rebuild its pipeline. - Deal momentum in biotech and pharma sectors rose 63% in Q1 2025 after falling 26% over the previous 12 months, indicating a market recovery despite ongoing tariff concerns.
- Vigil Neuroscience reports positive Phase 1 data for VG-3927, an oral TREM2 agonist, showing a favorable safety profile in healthy adults and Alzheimer's patients. - The trial demonstrated robust, dose-dependent reductions in sTREM2 levels in cerebrospinal fluid, indicating strong target engagement and potential neuroprotective effects. - Vigil plans to advance VG-3927 into a Phase 2 clinical trial in Q3 2025, using a 25mg once-daily oral dose based on Phase 1 findings. - VG-3927's unique mechanism aims to enhance microglial function without increasing inflammation, offering a differentiated approach to Alzheimer's treatment.
- The FDA has lifted the partial clinical hold on Vigil Neuroscience's Phase I trial of VG-3927, a treatment for neurodegenerative diseases, following a complete response from the company. - Interim data from the trial indicated VG-3927's safety, tolerability, and potential for once-daily dosing, alongside a sustained decline in soluble TREM2 levels in cerebrospinal fluid. - The Phase I trial has expanded to include Alzheimer's disease patients, including those with TREM2 or other disease-related genetic variations, to assess biomarker response. - Vigil Neuroscience plans to release complete Phase I data, including results from the Alzheimer's patient cohort, in the first quarter of next year.
